Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus
Lichen planus (LP) is a common, chronic relapsing inflammatory disorder of the skin and mucous membranes which often poses a major therapeutic challenge due to its refractory course. Novel pathogenesis-based therapies are urgently needed. As several studies have shown that IL-17 may contribute to LP...
Main Authors: | Farzan Solimani, Robert Pollmann, Thomas Schmidt, Ansgar Schmidt, Xiang Zheng, Rajkumar Savai, Stefan Mühlenbein, Julia Pickert, Verena Eubel, Christian Möbs, Rüdiger Eming, Michael Hertl |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01808/full |
Similar Items
-
Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels
by: Christopher Willy Schwarz, et al.
Published: (2020-09-01) -
Secukinumab-induced Oral Lichen Planus: A Report of Case and Review of Literature
by: Munise Daye, et al.
Published: (2021-08-01) -
Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01) -
Systematic review of immunomodulatory therapies for hidradenitis suppurativa
by: Lim SYD, et al.
Published: (2019-05-01) -
Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
by: Amy J. Petty, BS, et al.
Published: (2020-08-01)